A stubborn tendon injury can test your patience. It may begin as a minor ache after training, improve with rest or physical therapy, and then return as soon as activity ramps up again.
Part of the frustration is biological. Tendons do not heal in the same way muscles do. Their blood supply is relatively limited, their collagen structure is highly organized, and rebuilding tissue strong enough to tolerate repeated mechanical load takes time.
That is one reason BPC-157 has attracted so much attention in recovery and sports medicine. Researchers have been studying whether the peptide can influence some of the processes involved in repairing tendons, ligaments and other connective tissues.
There is real science behind that interest. But understanding what the research actually shows is more useful than simply calling BPC-157 a “healing peptide.”
Why are tendon injuries so difficult to heal?
A tendon connects muscle to bone and transfers the force produced by your muscles into movement. To do that reliably, it depends on a remarkably strong and organized structure built largely from tightly aligned collagen fibers.
When a tendon is injured, the repair process generally moves through three overlapping stages: inflammation, proliferation and remodeling. The body first responds to the injury and clears damaged tissue. Repair cells then begin producing new extracellular matrix and collagen. Over time, those collagen fibers reorganize and mature as the tendon attempts to regain strength and function.
The challenge is that a repaired tendon does not necessarily return completely to its original mechanical properties. Modern tendon research therefore looks beyond simply making new tissue. The goal is to understand how to encourage better-organized collagen, appropriate blood vessel development and meaningful functional recovery.
What is BPC-157?
BPC-157 is a synthetic peptide made from a sequence of 15 amino acids associated with a protein found in gastric tissue.
It was not originally developed specifically as a tendon treatment. Research has explored its effects across several biological systems, including tissue repair, inflammation, blood vessel formation and gastrointestinal protection. Over time, investigators also began studying BPC-157 in models of musculoskeletal injury.
A 2025 systematic review led by researchers at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center examined the available BPC-157 literature from an orthopedic and sports medicine perspective. The review identified studies involving tendon ruptures, ligament injuries, muscle damage and bone healing, with experimental findings suggesting that the peptide may interact with several processes involved in tissue repair.
That helps explain why interest in BPC-157 has moved beyond online peptide forums and into formal sports medicine research.
How might BPC-157 influence tendon repair?
There probably is not one single mechanism. The experimental literature points toward several connected parts of the repair process.
Blood vessel formation may be part of the story
Repairing tissue needs oxygen, nutrients and constant communication between cells. That depends partly on angiogenesis, the development of new blood vessels.
BPC-157 research has repeatedly examined vascular signaling and blood vessel formation. In tendon injury models, researchers have observed increased vascular responses alongside functional recovery.
That matters because vascularization plays an important role during repair, particularly in tissue such as tendons that naturally have a relatively limited blood supply.
Collagen organization matters just as much as collagen production
Collagen is not simply biological filler. For a tendon to work correctly, its collagen fibers need to become organized in a way that allows the tissue to tolerate substantial tensile force.
Research involving Achilles tendon-to-bone injury has reported improved collagen organization in animals treated with BPC-157, together with improvements in biomechanical measures of the repaired tissue. One Achilles tendon-to-bone study from the University of Zagreb Medical School remains frequently referenced in later BPC-157 musculoskeletal research.
That combination is important because stronger-looking tissue under a microscope is not enough. The repaired tendon ultimately has to function mechanically.
Inflammation is not something healing can simply switch off
Inflammation is part of normal repair. Excessive or prolonged inflammation can interfere with recovery, but eliminating the inflammatory response entirely is not the goal either. The body uses inflammatory signaling to coordinate the early stages of tissue healing.
Experimental BPC-157 research suggests the peptide may influence inflammatory pathways while supporting subsequent repair. Researchers are also investigating its interaction with the nitric oxide system, which is involved in vascular function, blood flow and multiple aspects of tissue healing.
What has research found specifically in tendons?
Several lines of experimental research are worth paying attention to.
Studies involving Achilles tendon-to-bone injuries have reported improvements in functional recovery, collagen organization and biomechanical characteristics after BPC-157 treatment.
Other studies have examined ligament injuries, muscle-tendon junctions and muscle-to-bone repair, with researchers reporting changes in tissue organization and functional recovery.
The research is still evolving. Another 2026 Achilles tendon study compared BPC-157, TB-500 and their combination after surgically repaired Achilles tendon injuries. Researchers evaluated the repaired tendons using biomechanical testing as well as histological and immunohistochemical analysis, including collagen types I and III. The BPC-157-treated tendons showed changes across several measures of repair.
So, should you try BPC-157 for a tendon injury?
The research gives BPC-157 a credible biological rationale for tendon and connective tissue repair.
A recent systematic review found consistent interest across tendon, ligament, muscle and bone models, and newer studies continue to investigate its effects on tendon healing.
Most of the musculoskeletal evidence is still preclinical, so we do not yet have the kind of large, well-controlled human tendon trials that would let us predict exactly how a person with a particular tendon injury will respond.
That does not make the research irrelevant. It places BPC-157 where it currently belongs scientifically: an emerging therapeutic candidate supported by substantial preclinical research, with human tendon research still developing.
A tendon problem is more than a peptide problem
One of the risks of looking for recovery solutions online is that the compound can become the entire story. But an Achilles tendon, rotator cuff or patellar tendon responds to biology and mechanical load – not to what happens to be trending.
The type of injury matters. So does how long it has been present, your training load, previous injuries, rehabilitation, medications, overall health and whether the problem is actually a tendon injury in the first place.
BPC-157 may eventually prove to have an important role in musculoskeletal recovery. The biology gives researchers good reasons to keep studying it. For someone considering peptide therapy today, however, the more useful question is not simply, “Does BPC-157 heal tendons?”
“Given my injury and my health profile, does exploring BPC-157 make sense for me?” That is a much better conversation to have with a clinician.
Where Fitstar comes in
Peptide therapy is about more than choosing a compound. Fitstar brings personalized recommendations, clinician-guided care and ongoing treatment management together in one experience.
Your health profile and goals inform a preliminary peptide protocol that can be reviewed with a licensed Fitstar clinician. If treatment is appropriate and available, Fitstar can also help you manage your protocol, track your experience and stay connected with your care team over time.
Because when you are trying to recover, understanding why a therapeutic approach may make sense is just as important as knowing its name.
Sources & Further Reading
Vasireddi N, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. Led by researchers at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Review of the musculoskeletal literature surrounding BPC-157, including tendon, ligament, muscle and bone injury. Full text | PubMed
Krivic A, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. University of Zagreb Medical School. This older study remains relevant because later BPC-157 musculoskeletal research and reviews continue to reference its tendon-to-bone healing findings. PubMed
Biçer O, et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Journal of Joint Diseases and Related Surgery. Direct experimental investigation of BPC-157 and TB-500 in Achilles tendon repair. Full study
Darrieutort-Laffite C, et al. (2024). Biology and physiology of tendon healing. Joint Bone Spine. Review of the cellular, extracellular matrix, growth factor and vascular processes involved in tendon healing. PubMed
Japjec M, et al. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats. Biomedicines. Research examining BPC-157 in the repair of injured muscle-tendon junctions. PubMed
Cerovecki T, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. Research examining BPC-157 in experimental ligament healing. PubMed